Compositions and methods for treatment of ovarian cancer
The disclosure provides compositions and methods for treating an ovarian cancer in a subject. More specifically, the disclosure provides microRNA (miRNA) inhibitor molecules that target to different miRNAs for treating different types of ovarian cancers in a subject. Furthermore, different modifications of miRNA inhibitor molecules as well as different derivatives of miRNA inhibitor molecules are also described.
1. A method of inhibiting proliferation of ovarian cancer cells, the method consisting of introducing into the cells of a patient in need thereof a composition consisting of a compound which inhibits expression or activity of a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 16 and 38, and a pharmaceutically acceptable carrier, wherein said compound inhibits proliferation of ovarian cancer cells.
2. The method of claim 1 , wherein said compound comprises a modified oligonucleotide consisting of 15 to 30 linked nucleosides, wherein the modified oligonucleotide has a nucleobase sequence that is complementary to SEQ ID NO: 16 or 38.
3. The method of claim 2 , wherein said modified oligonucleotide has a nucleobase sequence of SEQ ID NO: 56.
4. The method of claim 1 , wherein the ovarian cancer cell is selected from the group consisting of serous and endometrioid ovarian cancer.
5. A method for treating ovarian cancer in a human subject in need thereof, said method consisting of administering to said subject a pharmaceutical composition consisting of a modified oligonucleotide and a pharmaceutically acceptable carrier, wherein the modified oligonucleotide consists of 15 to 30 linked nucleosides and has a nucleobase sequence that is complementary to a nucleobase sequence selected from the group consisting of SEQ ID NOs: 16 and 38.
6. The method of claim 5 , wherein the modified oligonucleotide has a nucleobase sequence comprising at least 15 contiguous nucleobases of SEQ ID NO: 56.
7. The method of claim 5 , wherein the ovarian cancer is selected from the group consisting of serous and endometrioid ovarian cancer.
8. The method of claim 4 , wherein at least one internucleoside linkage of the modified oligonucleotide is a modified internucleoside linkage.
9. The method of claim 8 , wherein said modified internucleoside linkage is a phosphorothioate internucleoside linkage.
10. The method of claim 2 , wherein at least one nucleoside of the modified oligonucleotide comprises a modified sugar.
11. The method of claim 10 , wherein the modified sugar is a 2′-O-methoxyethyl sugar.
12. The method of claim 5 , wherein said composition is administered by any one of intravenous administration, subcutaneous administration, intratumoral administration, or chemoembolization.
13. The method of claim 5 , wherein at least one internucleoside linkage of the modified oligonucleotide is a modified internucleoside linkage.
14. The method of claim 13 , wherein said modified internucleoside linkage is a phosphorothioate internucleoside linkage.
15. The method of claim 5 , wherein at least one nucleoside of the modified oligonucleotide comprises a modified sugar.
16. The method of claim 15 , wherein the modified sugar is a 2′-O-methoxyethyl sugar.